Polatuzumab vedotin/bendamustine/rituximab (pola-BR) in R/R diffuse large B cell lymphoma with hemophagocytic lymphohistiocytosis

期刊论文
出版模式：

开放获取
发表日期：

2024年12月11日

查看全文

Chaoyu Wang,
Longrong Ran,
Xi Quan,
Chongling Hu,
Bingling Guo,
Dehong Huang,
Qing Xiao,
Xiaomei Zhang,
Jieping Li,
Zailin Yang,
Yao Liu

摘要

We have treated a rare case of elderly relapsed/refractory (R/R) duffuse large B cell lymphoma (DLBCL) with hemophagocytic lymphohistiocytosis (HLH) and SARS-CoV-2 infection, which achieved complete response (CR) without lymphoma-related symptoms after polatuzumab vedotin/bendamustine/rituximab (pola-BR) treatment. To the best of our knowledge, this is the first report of R/R DLBCL with HLH and Covid-19 treated with pola-BR, and the patient is still alive at the time of report. We found that polatuzumab vedotin may have a potential therapeutic effect on HLH and Covid-19.